Stockreport

LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment [Yahoo! Finance]

Lyell Immunopharma, Inc.  (LYEL) 
PDF LB Pharma's lead asset, LB-102, is a patent protected blood-brain barrier-optimized analog of amisulpride, a well-established antipsychotic widely used in Europe LB-1 [Read more]